首页 > 最新文献

Case Reports in Oncological Medicine最新文献

英文 中文
Oncocytic Carcinoma with Liver Metastasis: Unusual Treatment Strategies and Clinical Insights—A Case Report and Review of the Literature 伴有肝转移的肿瘤细胞癌:不寻常的治疗策略和临床启示--病例报告和文献综述
IF 0.9 Pub Date : 2024-03-28 DOI: 10.1155/2024/3039762
M. Hourani, S. Giridharan, F. Azribi, Hidayath Ansari, J. Ansari
We report a distinctive case of malignant oncocytic carcinoma originating in the pancreas, an organ rarely associated with such tumours. We discuss the diagnostic journey, highlighting the tumour's resemblance to renal cell carcinoma but without renal involvement. A significant aspect of this case is the successful and sustained response to combined immunotherapy and tyrosine kinase inhibitors, demonstrating a potential therapeutic pathway for similar rare cases. This study contributes to a deeper understanding of pancreatic oncocytic tumours and their management.
我们报告了一例起源于胰腺的恶性肿瘤细胞癌病例,胰腺是极少发生此类肿瘤的器官。我们讨论了诊断过程,强调了肿瘤与肾细胞癌的相似之处,但没有累及肾脏。该病例的一个重要方面是对联合免疫疗法和酪氨酸激酶抑制剂的成功和持续反应,为类似的罕见病例展示了一种潜在的治疗途径。这项研究有助于加深对胰腺肿瘤细胞瘤及其治疗的理解。
{"title":"Oncocytic Carcinoma with Liver Metastasis: Unusual Treatment Strategies and Clinical Insights—A Case Report and Review of the Literature","authors":"M. Hourani, S. Giridharan, F. Azribi, Hidayath Ansari, J. Ansari","doi":"10.1155/2024/3039762","DOIUrl":"https://doi.org/10.1155/2024/3039762","url":null,"abstract":"We report a distinctive case of malignant oncocytic carcinoma originating in the pancreas, an organ rarely associated with such tumours. We discuss the diagnostic journey, highlighting the tumour's resemblance to renal cell carcinoma but without renal involvement. A significant aspect of this case is the successful and sustained response to combined immunotherapy and tyrosine kinase inhibitors, demonstrating a potential therapeutic pathway for similar rare cases. This study contributes to a deeper understanding of pancreatic oncocytic tumours and their management.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140372399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET-CT Scans in Oncology Patients Treated with Hyaluronic Acid Filler: Not Always a Pitfall 使用透明质酸填充剂治疗肿瘤患者的 18F-FDG PET-CT 扫描:并非总是陷阱
IF 0.9 Pub Date : 2024-03-27 DOI: 10.1155/2024/5559093
I. Proietti, Chiara Battilotti, Francesca Svara, E. Tolino, N. Bernardini, N. Skroza, Luca Filippi, C. Potenza
The use of hyaluronic acid (HA) fillers in oncology patients undergoing PET-CT scans is a topic of debate due to potential interference with imaging accuracy. A 54-year-old female, postmelanoma metastasectomy in the parotid region with subsequent facial nerve palsy (FNP), received HA filler injections for facial symmetry and functional restoration. Follow-up PET-CT scans showed no interference or artifacts attributable to HA injection, allowing for accurate imaging results. This case suggests that HA fillers administered in oncology patients may not universally pose challenges or disrupt PET-CT imaging interpretation. Due to the possible false positives induced by fillers, the inclusion of aesthetic treatments in patients' anamnesis is a crucial step to accurately interpret PET-CT images. Although maintaining high level of caution in interpreting PET-CT results after filler injection is essential, our case emphasizes the safety of this procedure in oncology patients undergoing follow-up PET-CT scans.
在接受 PET-CT 扫描的肿瘤患者中使用透明质酸(HA)填充剂可能会影响成像的准确性,因此一直是一个争论不休的话题。一名 54 岁的女性患者在腮腺部位接受了黑色素瘤转移切除术,随后出现了面神经麻痹(FNP),为了恢复面部对称和功能,她接受了 HA 填充剂注射。随访的 PET-CT 扫描显示,HA 注射未产生干扰或伪影,因此成像结果准确无误。该病例表明,肿瘤患者注射 HA 填充剂并不普遍会对 PET-CT 成像解读造成挑战或干扰。由于填充物可能引起假阳性,因此在患者的病史中纳入美容治疗是准确解读 PET-CT 图像的关键步骤。虽然在注射填充剂后解读 PET-CT 结果时必须保持高度谨慎,但我们的病例强调了肿瘤患者接受 PET-CT 后续扫描时这一过程的安全性。
{"title":"18F-FDG PET-CT Scans in Oncology Patients Treated with Hyaluronic Acid Filler: Not Always a Pitfall","authors":"I. Proietti, Chiara Battilotti, Francesca Svara, E. Tolino, N. Bernardini, N. Skroza, Luca Filippi, C. Potenza","doi":"10.1155/2024/5559093","DOIUrl":"https://doi.org/10.1155/2024/5559093","url":null,"abstract":"The use of hyaluronic acid (HA) fillers in oncology patients undergoing PET-CT scans is a topic of debate due to potential interference with imaging accuracy. A 54-year-old female, postmelanoma metastasectomy in the parotid region with subsequent facial nerve palsy (FNP), received HA filler injections for facial symmetry and functional restoration. Follow-up PET-CT scans showed no interference or artifacts attributable to HA injection, allowing for accurate imaging results. This case suggests that HA fillers administered in oncology patients may not universally pose challenges or disrupt PET-CT imaging interpretation. Due to the possible false positives induced by fillers, the inclusion of aesthetic treatments in patients' anamnesis is a crucial step to accurately interpret PET-CT images. Although maintaining high level of caution in interpreting PET-CT results after filler injection is essential, our case emphasizes the safety of this procedure in oncology patients undergoing follow-up PET-CT scans.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140377433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report. 阿特珠单抗治疗可能引起的暂时性中性粒细胞减少性免疫相关不良事件后,多关节炎伴活动性腱鞘炎的显著延迟发展:新病例报告。
IF 0.9 Pub Date : 2024-02-08 eCollection Date: 2024-01-01 DOI: 10.1155/2024/1566299
Yoshitaka Saito, Yoh Takekuma, Hajime Asahina, Ryo Hisada, Mitsuru Sugawara

Immune checkpoint inhibitors have drastically improved cancer treatment. However, they may induce immune-related adverse events (irAEs). Here, we report a case of significantly delayed rheumatic irAEs (Rh-irAEs) with prior possible temporary neutropenic irAEs in a patient with atezolizumab-treated non-small-cell lung cancer and its management. A man in his sixties received atezolizumab monotherapy as the sixth-line treatment. He experienced an infusion-related reaction (fever) during the first cycle. On day 22 of cycle 2, grade 4 neutropenia suddenly appeared, but it disappeared on the next day. Cycle 3 was initiated after seven days; the patient did not exhibit any symptoms for approximately 500 days. However, on day 534 (day 1 of cycle 21), the patient complained of pain in the shoulders, back, and wrists. On day 644, the shoulder and back pain worsened with obvious swelling of the fingers. We thus suspended treatment and consulted a rheumatologist. A diagnosis of polyarthritis with active tenosynovitis was made based on joint ultrasound and laboratory tests. Prednisolone 15 mg attenuated the symptoms, allowing suspension of analgesics; however, dose reduction from 15 mg/day was difficult because of symptom flares. Finally, iguratimod 25 mg twice daily was initiated on day 764; prednisolone was reduced to 10 mg without flares, and its dosage was slowly reduced to 5 mg/day. Although irAEs exhibit multisystem features, delayed development of polyarthritis with active tenosynovitis after possible temporary neutropenic irAEs is rare. Thus, irAEs need to be monitored for a long time in patients with suspected irAE development even if it appears transiently.

免疫检查点抑制剂大大改善了癌症治疗。然而,它们可能会诱发免疫相关不良事件(irAEs)。在此,我们报告了一例atezolizumab治疗的非小细胞肺癌患者出现明显延迟的风湿性irAEs(Rh-irAEs)以及之前可能出现的暂时性中性粒细胞减少性irAEs及其处理方法。一名六十多岁的男子接受了阿特珠单抗单药治疗,作为六线治疗。在第一周期,他出现了输液相关反应(发烧)。在第二周期的第 22 天,他突然出现了 4 级中性粒细胞减少症,但第二天就消失了。第 3 周期在 7 天后开始;患者在大约 500 天内没有出现任何症状。然而,在第 534 天(第 21 个周期的第 1 天),患者抱怨肩膀、背部和手腕疼痛。第 644 天,肩部和背部疼痛加剧,手指明显肿胀。因此,我们暂停了治疗,并咨询了风湿病专家。根据关节超声波和实验室检查结果,诊断为多关节炎伴活动性腱鞘炎。泼尼松龙 15 毫克可减轻症状,从而可以暂停使用镇痛药;然而,由于症状复发,很难从每天 15 毫克的剂量开始减量。最后,在第764天开始使用伊古拉替莫德(iguratimod)25毫克,每天两次;泼尼松龙减少到10毫克,但症状没有复发,其剂量慢慢减少到每天5毫克。虽然虹膜睫状体异常表现出多系统特征,但在可能出现暂时性中性粒细胞减少性虹膜睫状体异常后延迟发展为多关节炎伴活动性腱鞘炎的情况并不多见。因此,对于疑似出现虹膜睫状体异常的患者,即使是一过性的虹膜睫状体异常,也需要对其进行长期监测。
{"title":"Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report.","authors":"Yoshitaka Saito, Yoh Takekuma, Hajime Asahina, Ryo Hisada, Mitsuru Sugawara","doi":"10.1155/2024/1566299","DOIUrl":"10.1155/2024/1566299","url":null,"abstract":"<p><p>Immune checkpoint inhibitors have drastically improved cancer treatment. However, they may induce immune-related adverse events (irAEs). Here, we report a case of significantly delayed rheumatic irAEs (Rh-irAEs) with prior possible temporary neutropenic irAEs in a patient with atezolizumab-treated non-small-cell lung cancer and its management. A man in his sixties received atezolizumab monotherapy as the sixth-line treatment. He experienced an infusion-related reaction (fever) during the first cycle. On day 22 of cycle 2, grade 4 neutropenia suddenly appeared, but it disappeared on the next day. Cycle 3 was initiated after seven days; the patient did not exhibit any symptoms for approximately 500 days. However, on day 534 (day 1 of cycle 21), the patient complained of pain in the shoulders, back, and wrists. On day 644, the shoulder and back pain worsened with obvious swelling of the fingers. We thus suspended treatment and consulted a rheumatologist. A diagnosis of polyarthritis with active tenosynovitis was made based on joint ultrasound and laboratory tests. Prednisolone 15 mg attenuated the symptoms, allowing suspension of analgesics; however, dose reduction from 15 mg/day was difficult because of symptom flares. Finally, iguratimod 25 mg twice daily was initiated on day 764; prednisolone was reduced to 10 mg without flares, and its dosage was slowly reduced to 5 mg/day. Although irAEs exhibit multisystem features, delayed development of polyarthritis with active tenosynovitis after possible temporary neutropenic irAEs is rare. Thus, irAEs need to be monitored for a long time in patients with suspected irAE development even if it appears transiently.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10869192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beta-HCG Secretion by a Pulmonary Choriocarcinoma in a Male Patient 一名男性患者肺绒毛膜癌分泌的 Beta-HCG
IF 0.9 Pub Date : 2024-01-27 DOI: 10.1155/2024/8731806
Brecht Devos, Cedric Willemse, Mira Sterckx, Johan Debruyne, Inge Stappaerts, Tom Van den Mooter, Marjan Hertoghs, Pascale Abrams
Background. Paraneoplastic secretion of beta-subunit of human chorionic gonadotropin (β-HCG) in pulmonary carcinoma is rare. Case Presentation. A 65-year-old man presented with bilateral gynaecomastia with abnormally high levels of β-hCG and elevated oestradiol, progesterone, and testosterone levels on April 7, 2023. After excluding testicular malignancy, CT scan of the chest and abdomen revealed bilateral pulmonary lesions. Transthoracic biopsy confirmed malignancy with choriocarcinoma. MRI of the brain showed a solitary brain metastasis, while on a subsequent 18F-FDG PET/CT, no other metastatic lesions were seen. The patient was treated with chemoimmunotherapy carboplatin-etoposide-pembrolizumab with good partial response. Conclusion. Our case of a presumably stage IV dedifferentiated mNSCLC presenting as an extragonadal β-hCG secreting pulmonary choriocarcinoma is a very rare tumor with a poor prognosis. Its biology, origin, and treatment remain to be elucidated. Cancer genome sequencing is necessary for the identification of the origin and seeking treatment.
背景。人绒毛膜促性腺激素 beta 亚基(β-HCG)在肺癌中的副肿瘤性分泌非常罕见。病例介绍。一名 65 岁的男性于 2023 年 4 月 7 日出现双侧妇科肿瘤,β-hCG 水平异常高,雌二醇、孕酮和睾酮水平升高。在排除睾丸恶性肿瘤后,胸部和腹部 CT 扫描发现双侧肺部病变。经胸活检证实为绒毛膜癌。脑部核磁共振成像显示有一个单发的脑转移灶,而在随后的18F-FDG PET/CT检查中,没有发现其他转移病灶。患者接受了卡铂-埃托泊苷-pembrolizumab化疗免疫疗法,部分反应良好。结论我们的病例是一种非常罕见、预后较差的肿瘤,患者可能是IV期低分化mNSCLC,表现为对角线外β-hCG分泌型肺绒毛膜癌。其生物学特性、起源和治疗方法仍有待阐明。癌症基因组测序是确定起源和寻求治疗的必要条件。
{"title":"Beta-HCG Secretion by a Pulmonary Choriocarcinoma in a Male Patient","authors":"Brecht Devos, Cedric Willemse, Mira Sterckx, Johan Debruyne, Inge Stappaerts, Tom Van den Mooter, Marjan Hertoghs, Pascale Abrams","doi":"10.1155/2024/8731806","DOIUrl":"https://doi.org/10.1155/2024/8731806","url":null,"abstract":"Background. Paraneoplastic secretion of beta-subunit of human chorionic gonadotropin (β-HCG) in pulmonary carcinoma is rare. Case Presentation. A 65-year-old man presented with bilateral gynaecomastia with abnormally high levels of β-hCG and elevated oestradiol, progesterone, and testosterone levels on April 7, 2023. After excluding testicular malignancy, CT scan of the chest and abdomen revealed bilateral pulmonary lesions. Transthoracic biopsy confirmed malignancy with choriocarcinoma. MRI of the brain showed a solitary brain metastasis, while on a subsequent 18F-FDG PET/CT, no other metastatic lesions were seen. The patient was treated with chemoimmunotherapy carboplatin-etoposide-pembrolizumab with good partial response. Conclusion. Our case of a presumably stage IV dedifferentiated mNSCLC presenting as an extragonadal β-hCG secreting pulmonary choriocarcinoma is a very rare tumor with a poor prognosis. Its biology, origin, and treatment remain to be elucidated. Cancer genome sequencing is necessary for the identification of the origin and seeking treatment.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139592432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Peritoneal Serous Cancer: A Case Report of a Tumor in the Rectovaginal Septum 原发性腹膜浆液性癌:直肠阴道隔肿瘤病例报告
IF 0.9 Pub Date : 2024-01-16 DOI: 10.1155/2024/5093727
Analy Herrera-Torres, C. Parra-Torres, Gabriela C. Alamilla García, María del Rocío Thompson Bonilla, Óscar Manuel García Córdova, Alfredo Padilla Martínez, Rodolfo Iván Lara Ruíz, Esther Ramírez Moreno
Peritoneal cancer is the invasion by malignant cells of serous membrane that lines the abdominal cavity, the viscera, and the coelom of the amniotes. Histologically, it is indistinguishable from ovarian counterpart, although in the former, it commonly involves the ovary only superficially, or it may totally lack an ovarian component, but with extensive involvement of the peritoneum, calcified perihepatic peritoneal nodules, or involvement of the omentum, in most cases. The current study describes the case of a 54-year-old female patient referring a history of colitis and dairy intolerance. A transvaginal ultrasound and a computed tomography (CT) scan revealed a tumor measuring 70×61×63 mm. CA-125 serum levels were 880 U/ml. Laparotomy surgery was indicated, and tumor was found at the level of the rectovaginal septum without evidence of metastasis. Tumor dissection and protective colostomy with loop sigmoid colon were performed. A pathological study gave a diagnosis of a high-grade peritoneal serous carcinoma with a micropapillary pattern. The present study describes the case of papillary serous peritoneal cancer presented as a single tumor mass without extensive involvement of the peritoneum. Additionally, the need for routine tests for its diagnosis and documenting hormonal alterations as the cause of its origin are suggested.
腹膜癌是指恶性细胞侵袭腹腔、内脏和羊膜的浆膜。在组织学上,腹膜癌与卵巢癌无异,但前者通常仅累及卵巢表层,或完全没有卵巢成分,但在大多数病例中,腹膜广泛受累,肝周腹膜结节钙化或网膜受累。本研究描述了一例 54 岁女性患者的病例,她曾有结肠炎和乳制品不耐受病史。经阴道超声波检查和计算机断层扫描(CT)显示肿瘤大小为 70×61×63 毫米。CA-125血清水平为880 U/ml。医生建议进行腹腔镜手术,发现肿瘤位于直肠阴道隔水平,无转移迹象。患者接受了肿瘤切除术和带环状乙状结肠的保护性结肠造口术。病理检查诊断为高级别腹膜浆液性癌,伴有微乳头状形态。本研究描述了一例表现为单个肿瘤肿块且未广泛累及腹膜的乳头状浆液性腹膜癌。此外,本研究还提出了常规检查诊断的必要性,并记录了激素变化的病因。
{"title":"Primary Peritoneal Serous Cancer: A Case Report of a Tumor in the Rectovaginal Septum","authors":"Analy Herrera-Torres, C. Parra-Torres, Gabriela C. Alamilla García, María del Rocío Thompson Bonilla, Óscar Manuel García Córdova, Alfredo Padilla Martínez, Rodolfo Iván Lara Ruíz, Esther Ramírez Moreno","doi":"10.1155/2024/5093727","DOIUrl":"https://doi.org/10.1155/2024/5093727","url":null,"abstract":"Peritoneal cancer is the invasion by malignant cells of serous membrane that lines the abdominal cavity, the viscera, and the coelom of the amniotes. Histologically, it is indistinguishable from ovarian counterpart, although in the former, it commonly involves the ovary only superficially, or it may totally lack an ovarian component, but with extensive involvement of the peritoneum, calcified perihepatic peritoneal nodules, or involvement of the omentum, in most cases. The current study describes the case of a 54-year-old female patient referring a history of colitis and dairy intolerance. A transvaginal ultrasound and a computed tomography (CT) scan revealed a tumor measuring 70×61×63 mm. CA-125 serum levels were 880 U/ml. Laparotomy surgery was indicated, and tumor was found at the level of the rectovaginal septum without evidence of metastasis. Tumor dissection and protective colostomy with loop sigmoid colon were performed. A pathological study gave a diagnosis of a high-grade peritoneal serous carcinoma with a micropapillary pattern. The present study describes the case of papillary serous peritoneal cancer presented as a single tumor mass without extensive involvement of the peritoneum. Additionally, the need for routine tests for its diagnosis and documenting hormonal alterations as the cause of its origin are suggested.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139528506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic Ovarian Serous Adenocarcinoma Clinically Presenting as Inflammatory Breast Cancer 临床表现为炎症性乳腺癌的转移性卵巢浆液性腺癌
IF 0.9 Pub Date : 2024-01-10 DOI: 10.1155/2024/4756335
Lingling Xian, Rachel Hunter, Emily Smith, Rasha Mohammed, C. Madelaire, Guillermo A. Herrera, Rodney E. Shackelford
Metastatic disease to the breast is a rare event, accounting for 0.5-2% of all breast cancers. Outside of metastases from the contralateral breast, malignant ovarian epithelial tumors are the most common origin of these metastases. Here, we present a very rare case of a high-grade ovarian serous adenocarcinoma presenting clinically as inflammatory breast cancer in a 70-year-old woman.
转移到乳房的疾病很少见,占所有乳腺癌的 0.5%-2%。除对侧乳房转移外,恶性卵巢上皮肿瘤是最常见的转移源。在这里,我们介绍了一例非常罕见的病例,一位 70 岁的妇女在临床上表现为炎症性乳腺癌的高级别卵巢浆液性腺癌。
{"title":"Metastatic Ovarian Serous Adenocarcinoma Clinically Presenting as Inflammatory Breast Cancer","authors":"Lingling Xian, Rachel Hunter, Emily Smith, Rasha Mohammed, C. Madelaire, Guillermo A. Herrera, Rodney E. Shackelford","doi":"10.1155/2024/4756335","DOIUrl":"https://doi.org/10.1155/2024/4756335","url":null,"abstract":"Metastatic disease to the breast is a rare event, accounting for 0.5-2% of all breast cancers. Outside of metastases from the contralateral breast, malignant ovarian epithelial tumors are the most common origin of these metastases. Here, we present a very rare case of a high-grade ovarian serous adenocarcinoma presenting clinically as inflammatory breast cancer in a 70-year-old woman.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139439682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Case of Nasal Sarcoma with BCOR Internal Tandem Duplication Showing Complete Pathologic Response to the VDC-IE Chemotherapy Protocol. 一例罕见的鼻肉瘤 BCOR 内部串联重复病例对 VDC-IE 化疗方案显示出完全病理反应。
IF 0.9 Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI: 10.1155/2023/5546323
Samer Salah, Maher A Sughayer, Omar Jaber, Nebras Abu Abed, Fatena Ajlouni, Wisam Al Gargaz, Ramiz Abu Hijlih, Fawzi Abuhijla, Akram Al-Ibraheem, Farah Alul, Walid Naser

Sarcoma with BCOR genetic alteration is an exceptionally rare and emerging subtype of sarcoma. It is categorized into two types: BCOR-related gene fusions such as BCOR::CCNB3 sarcomas and other BCOR-rearranged sarcoma and sarcomas with internal tandem duplication of BCOR genes such as infantile undifferentiated round cell sarcomas and primitive myxoid mesenchymal tumors of infancy. BCOR::CCNB3 sarcomas predominantly arise in bone rather than soft tissue and exhibit a higher occurrence in children and adolescent males, whereas sarcomas with BCOR internal tandem duplication show a wider age range but usually arise in the first year of life. Due to their rarity, there is ongoing debate and uncertainty regarding the best treatment approach, with a lack of specific clinical trials addressing these tumors. In this report, we present a unique case of sarcoma with internal tandem duplication of BCOR gene originating in the nasal region. The tumor was successfully and completely resected using the standard VDC-IE chemotherapy protocol, resulting in an unprecedented 100 percent tumor necrosis. The patient has completed the protocol and remains recurrence-free 13 months after diagnosis. This case suggests potential efficacy of the standard VDC-IE protocol in achieving remarkable responses in BCOR rearrangement sarcomas, including the internal tandem duplication subtype. However, further studies are needed to determine the optimal treatment strategies for this disease.

具有 BCOR 基因改变的肉瘤是一种异常罕见的新兴亚型肉瘤。它分为两种类型:BCOR 相关基因融合(如 BCOR::CCNB3肉瘤和其他 BCOR 重排肉瘤)和 BCOR 基因内部串联重复的肉瘤(如婴儿未分化圆细胞肉瘤和婴儿原始肌间质肿瘤)。BCOR::CCNB3肉瘤主要发生在骨骼而非软组织,儿童和青少年男性发病率较高,而BCOR内部串联重复的肉瘤发病年龄范围较广,但通常发生在出生后第一年。由于其罕见性,关于最佳治疗方法的争论和不确定性一直存在,并且缺乏针对这些肿瘤的特定临床试验。在本报告中,我们介绍了一例独特的鼻部 BCOR 基因内部串联重复肉瘤病例。我们采用标准的 VDC-IE 化疗方案成功地完全切除了肿瘤,肿瘤坏死率达到前所未有的 100%。患者已完成方案治疗,确诊后 13 个月仍未复发。该病例表明,标准 VDC-IE 方案在 BCOR 重排肉瘤(包括内部串联重复亚型)中取得显著疗效的潜在功效。然而,要确定这种疾病的最佳治疗策略,还需要进一步的研究。
{"title":"A Rare Case of Nasal Sarcoma with BCOR Internal Tandem Duplication Showing Complete Pathologic Response to the VDC-IE Chemotherapy Protocol.","authors":"Samer Salah, Maher A Sughayer, Omar Jaber, Nebras Abu Abed, Fatena Ajlouni, Wisam Al Gargaz, Ramiz Abu Hijlih, Fawzi Abuhijla, Akram Al-Ibraheem, Farah Alul, Walid Naser","doi":"10.1155/2023/5546323","DOIUrl":"10.1155/2023/5546323","url":null,"abstract":"<p><p>Sarcoma with <i>BCOR</i> genetic alteration is an exceptionally rare and emerging subtype of sarcoma. It is categorized into two types: <i>BCOR</i>-related gene fusions such as <i>BCOR::CCNB3</i> sarcomas and other <i>BCOR</i>-rearranged sarcoma and sarcomas with internal tandem duplication of <i>BCOR</i> genes such as infantile undifferentiated round cell sarcomas and primitive myxoid mesenchymal tumors of infancy. <i>BCOR::CCNB3</i> sarcomas predominantly arise in bone rather than soft tissue and exhibit a higher occurrence in children and adolescent males, whereas sarcomas with <i>BCOR</i> internal tandem duplication show a wider age range but usually arise in the first year of life. Due to their rarity, there is ongoing debate and uncertainty regarding the best treatment approach, with a lack of specific clinical trials addressing these tumors. In this report, we present a unique case of sarcoma with internal tandem duplication of <i>BCOR</i> gene originating in the nasal region. The tumor was successfully and completely resected using the standard VDC-IE chemotherapy protocol, resulting in an unprecedented 100 percent tumor necrosis. The patient has completed the protocol and remains recurrence-free 13 months after diagnosis. This case suggests potential efficacy of the standard VDC-IE protocol in achieving remarkable responses in <i>BCOR</i> rearrangement sarcomas, including the internal tandem duplication subtype. However, further studies are needed to determine the optimal treatment strategies for this disease.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10761225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139089904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report of Probable DRESS Syndrome Associated with Ribociclib. 可能与利博西尼相关的DRESS综合征病例报告。
IF 0.9 Pub Date : 2023-11-23 eCollection Date: 2023-01-01 DOI: 10.1155/2023/7904950
Florian Carneiro, Marine Bove, Frédérique Beau-Salinas, Tevy San, Pierre Combe

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but known and potentially severe side effect of drugs. The recent development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as ribociclib, has considerably improved the management of hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer. Here, we present the case of an 83-year-old patient who developed a probable DRESS syndrome induced by ribociclib, presenting with fever, eosinophilia, rash, and hepatic cytolysis. The RegiSCAR score was 4. The symptomatology evolved favorably with topical and systemic corticosteroids, without any sequel. Another CDK4/6 inhibitor, palbociclib, was introduced later without any cross-toxicity and with an excellent therapeutic response for more than 3 years.

药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)是一种罕见但已知且可能严重的药物副作用。最近开发的细胞周期蛋白依赖性激酶4/6 (CDK4/6)抑制剂,如ribociclib,已经大大改善了激素受体阳性(HR+)和HER2阴性(HER2-)晚期乳腺癌的管理。在这里,我们报告了一例83岁的患者,他发展为可能由核糖素引起的DRESS综合征,表现为发烧、嗜酸性粒细胞增多、皮疹和肝细胞溶解。RegiSCAR评分为4分。局部和全身皮质类固醇的症状发展良好,没有任何后遗症。另一种CDK4/6抑制剂palbociclib后来被引入,没有任何交叉毒性,并且在3年多的时间里有很好的治疗反应。
{"title":"Case Report of Probable DRESS Syndrome Associated with Ribociclib.","authors":"Florian Carneiro, Marine Bove, Frédérique Beau-Salinas, Tevy San, Pierre Combe","doi":"10.1155/2023/7904950","DOIUrl":"10.1155/2023/7904950","url":null,"abstract":"<p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but known and potentially severe side effect of drugs. The recent development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as ribociclib, has considerably improved the management of hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer. Here, we present the case of an 83-year-old patient who developed a probable DRESS syndrome induced by ribociclib, presenting with fever, eosinophilia, rash, and hepatic cytolysis. The RegiSCAR score was 4. The symptomatology evolved favorably with topical and systemic corticosteroids, without any sequel. Another CDK4/6 inhibitor, palbociclib, was introduced later without any cross-toxicity and with an excellent therapeutic response for more than 3 years.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138476850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inv(3) Acute Myeloid Leukemia in a Young Adult and Review of the Literature 1例青壮年急性髓系白血病及文献回顾
Pub Date : 2023-11-11 DOI: 10.1155/2023/6628492
Carlee Blakemore, Sudarshawn Damodharan, Diane Puccetti
Acute myeloid leukemia (AML) with the high-risk variant inv(3)/t(3;3) or t(3;3)(q21;26.2) is rarely seen in the pediatric and young adult population. It is associated with poor outcomes with ineffective therapeutic options. Here, we present a case of an 18-year-old female with treatment refractory inv(3) AML in whom remission was unable to be obtained. Better treatment options are needed given the increased resistance to traditional therapy this subtype portrays. Here, we review the literature on pediatric and young adult inv(3) AML along with newer therapeutic options.
具有高风险变异inv(3)/t(3;3)或t(3;3)(q21;26.2)的急性髓性白血病(AML)在儿科和青年人群中罕见。它与治疗方案无效的不良结果有关。在这里,我们提出了一例18岁的女性治疗难治性inv(3) AML,无法获得缓解。鉴于该亚型所描述的对传统疗法的耐药性增加,需要更好的治疗方案。在这里,我们回顾了儿科和青少年AML的文献以及新的治疗方案。
{"title":"Inv(3) Acute Myeloid Leukemia in a Young Adult and Review of the Literature","authors":"Carlee Blakemore, Sudarshawn Damodharan, Diane Puccetti","doi":"10.1155/2023/6628492","DOIUrl":"https://doi.org/10.1155/2023/6628492","url":null,"abstract":"Acute myeloid leukemia (AML) with the high-risk variant inv(3)/t(3;3) or t(3;3)(q21;26.2) is rarely seen in the pediatric and young adult population. It is associated with poor outcomes with ineffective therapeutic options. Here, we present a case of an 18-year-old female with treatment refractory inv(3) AML in whom remission was unable to be obtained. Better treatment options are needed given the increased resistance to traditional therapy this subtype portrays. Here, we review the literature on pediatric and young adult inv(3) AML along with newer therapeutic options.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135041975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ACTH-Producing Neuroendocrine Carcinoma of the Liver with Cushing's Syndrome. 产生ACTH的神经内分泌肝癌伴库欣综合征。
IF 0.9 Pub Date : 2023-09-26 eCollection Date: 2023-01-01 DOI: 10.1155/2023/9946271
Mudassar Sandozi, Saagar Pamulapati, Aniqa Zaidi, Zuzanna Stuart, Sneha Pamulapati, Ajay Doniparthi

Paraneoplastic Cushing's syndrome arises when neuroendocrine tumors cause excess glucocorticoid production. We report a case of ectopic ACTH-producing liver neuroendocrine tumor. A 71 y.o. female with a history of rectal squamous carcinoma presented with fatigue and diffuse swelling. Liver biopsy revealed metastatic neuroendocrine carcinoma. Workup revealed markedly elevated morning cortisol and ACTH. Overnight dexamethasone suppression testing and positive immunostaining for ACTH on biopsy suggested paraneoplastic Cushing's syndrome secondary to neuroendocrine hepatic tumors with bony metastasis. This explained the patient's persistent anasarca, hyperglycemia, and electrolyte abnormalities. Despite multiple interventions, the patient's clinical status declined, and she expired.

当神经内分泌肿瘤引起过量的糖皮质激素产生时,就会出现副肿瘤性库欣综合征。我们报告一例异位促肾上腺皮质激素产生的肝脏神经内分泌肿瘤。一位71岁女性,有直肠鳞状细胞癌病史,表现为疲劳和弥漫性肿胀。肝活检显示有转移性神经内分泌癌。检查显示早晨皮质醇和促肾上腺皮质激素明显升高。隔夜地塞米松抑制试验和活检中ACTH免疫染色阳性表明副肿瘤性库欣综合征继发于伴有骨转移的神经内分泌肝肿瘤。这解释了患者持续性肛门痉挛、高血糖和电解质异常。尽管采取了多种干预措施,但患者的临床状况有所下降,并已过期。
{"title":"ACTH-Producing Neuroendocrine Carcinoma of the Liver with Cushing's Syndrome.","authors":"Mudassar Sandozi,&nbsp;Saagar Pamulapati,&nbsp;Aniqa Zaidi,&nbsp;Zuzanna Stuart,&nbsp;Sneha Pamulapati,&nbsp;Ajay Doniparthi","doi":"10.1155/2023/9946271","DOIUrl":"https://doi.org/10.1155/2023/9946271","url":null,"abstract":"<p><p>Paraneoplastic Cushing's syndrome arises when neuroendocrine tumors cause excess glucocorticoid production. We report a case of ectopic ACTH-producing liver neuroendocrine tumor. A 71 y.o. female with a history of rectal squamous carcinoma presented with fatigue and diffuse swelling. Liver biopsy revealed metastatic neuroendocrine carcinoma. Workup revealed markedly elevated morning cortisol and ACTH. Overnight dexamethasone suppression testing and positive immunostaining for ACTH on biopsy suggested paraneoplastic Cushing's syndrome secondary to neuroendocrine hepatic tumors with bony metastasis. This explained the patient's persistent anasarca, hyperglycemia, and electrolyte abnormalities. Despite multiple interventions, the patient's clinical status declined, and she expired.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41113057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Case Reports in Oncological Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1